Applied Proteomics

About Applied Proteomics

Applied Proteomics Inc. (API) operates at the intersection of diagnostics and personalized medicine, focusing on the application of proteomics for developing tools that enable better medical decisions. The company was co-founded in May 2007 by Dr. David Agus, a prominent oncologist and researcher, and Dr. Danny Hillis, a specialist in computer science and systems engineering. The foundation of the company stemmed from Dr. Agus's insight into protein measurement as a powerful diagnostic tool and Dr. Hillis's recognition that the complexity of proteomics required a systems engineering approach to overcome previous limitations.

The company's core business revolves around a proprietary proteomics platform designed for protein-based biomarker discovery, which it aims to make a replicable and industrial-scale application. This platform integrates advanced instrumentation, high-speed computing, and extensive genome annotations with strict, regimented operating procedures and quality controls across the entire process, from sample collection to data analysis. Applied Proteomics generates revenue by developing and commercializing novel molecular diagnostic tests. Its target clients are healthcare providers, offering them tools for earlier disease detection and more precise patient treatment before symptoms advance.

A key product developed by Applied Proteomics is the SimpliPro Colon™ Test, a blood-based test for assessing the risk of colorectal cancer and advanced adenoma. This test functions by measuring 11 distinct protein markers associated with these conditions, offering a convenient alternative to traditional screening methods to improve patient compliance with colonoscopy referrals. The company leverages mass spectrometry for its discovery platform and clinical assays, establishing a high-capacity CLIA laboratory to support its product launch and ongoing research. Through strategic collaborations, such as one with Agilent Technologies, API has worked to enhance the capabilities of its highly multiplexed protein assays. The company has successfully raised significant capital, including a $50.4M Series C funding round in 2013, to support commercialization and further development of its diagnostic pipeline.